Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1956 1
1957 1
1958 2
1960 2
1961 1
1994 1
1995 1
1996 10
1997 24
1998 27
1999 32
2000 36
2001 65
2002 90
2003 110
2004 125
2005 143
2006 134
2007 133
2008 129
2009 131
2010 128
2011 144
2012 127
2013 131
2014 127
2015 124
2016 106
2017 116
2018 96
2019 101
2020 103
2021 90
2022 83
2023 107
2024 57

Text availability

Article attribute

Article type

Publication date

Search Results

2,559 results

Results by year

Filters applied: . Clear all
Page 1
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Cuzick J, Sestak I, Forbes JF, Dowsett M, Cawthorn S, Mansel RE, Loibl S, Bonanni B, Evans DG, Howell A; IBIS-II investigators. Cuzick J, et al. Lancet. 2020 Jan 11;395(10218):117-122. doi: 10.1016/S0140-6736(19)32955-1. Epub 2019 Dec 12. Lancet. 2020. PMID: 31839281 Free PMC article. Clinical Trial.
Here, we report blinded long-term follow-up results for the IBIS-II trial, which compared anastrozole with placebo, with the objective of determining the efficacy of anastrozole for preventing breast cancer (both invasive and ductal carcinoma in situ) in the post-tr …
Here, we report blinded long-term follow-up results for the IBIS-II trial, which compared anastrozole with placebo, with the objectiv …
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Iwase T, Saji S, Iijima K, Higaki K, Ohtani S, Sato Y, Hozumi Y, Hasegawa Y, Yanagita Y, Takei H, Tanaka M, Masuoka H, Tanabe M, Egawa C, Komoike Y, Nakamura T, Ohtsu H, Mukai H. Iwase T, et al. J Clin Oncol. 2023 Jun 20;41(18):3329-3338. doi: 10.1200/JCO.22.00577. Epub 2023 Apr 20. J Clin Oncol. 2023. PMID: 37079878 Clinical Trial.
PATIENTS AND METHODS: This prospective, randomized, multicenter open-label phase III study assessed the effect of extending anastrozole treatment for an additional 5 years in postmenopausal patients who were disease-free after treatment with either 5 years of anastrozol …
PATIENTS AND METHODS: This prospective, randomized, multicenter open-label phase III study assessed the effect of extending anastrozole …
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Zhang P, Zhang Q, Tong Z, Sun T, Li W, Ouyang Q, Hu X, Cheng Y, Yan M, Pan Y, Teng Y, Yan X, Wang Y, Xie W, Zeng X, Wang X, Hu C, Geng C, Zhang H, Li W, Wu X, Zhong J, Xu J, Shi Y, Wei W, Bayaxi N, Zhu X, Xu B. Zhang P, et al. Lancet Oncol. 2023 Jun;24(6):646-657. doi: 10.1016/S1470-2045(23)00172-9. Epub 2023 May 11. Lancet Oncol. 2023. PMID: 37182538 Clinical Trial.
We aimed to assess the efficacy and safety of dalpiciclib plus letrozole or anastrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer who had no previous systemic therapy in the advanced setting. ...INTERPRETATION: Our findings suggest th …
We aimed to assess the efficacy and safety of dalpiciclib plus letrozole or anastrozole in patients with hormone receptor-positive, H …
Anastrozole-Associated Lichenoid Eruption.
Ivory J, Sochat M, Galatowitsch J, Ghani S. Ivory J, et al. Am J Ther. 2020 Nov/Dec;27(6):e658-e660. doi: 10.1097/MJT.0000000000001029. Am J Ther. 2020. PMID: 33156584 No abstract available.
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
Hurvitz SA, Bardia A, Quiroga V, Park YH, Blancas I, Alonso-Romero JL, Vasiliev A, Adamchuk H, Salgado M, Yardley DA, Berzoy O, Zamora-Auñón P, Chan D, Spera G, Xue C, Ferreira E, Badovinac Crnjevic T, Pérez-Moreno PD, López-Valverde V, Steinseifer J, Fernando TM, Moore HM, Fasching PA; coopERA Breast Cancer study group. Hurvitz SA, et al. Lancet Oncol. 2023 Sep;24(9):1029-1041. doi: 10.1016/S1470-2045(23)00268-1. Lancet Oncol. 2023. PMID: 37657462 Free article. Clinical Trial.
Participants were randomly assigned (1:1) to giredestrant 30 mg oral daily or anastrozole 1 mg oral daily on days 1-14 (window-of-opportunity phase) via an interactive web-based system with permuted-block randomisation with block size of four. ...Serious adverse events occ …
Participants were randomly assigned (1:1) to giredestrant 30 mg oral daily or anastrozole 1 mg oral daily on days 1-14 (window-of-opp …
Anastrozole Regulates Fatty Acid Synthase in Breast Cancer.
Cairns J, Ingle JN, Kalari KR, Goetz MP, Weinshilboum RM, Gao H, Li H, Bari MG, Wang L. Cairns J, et al. Mol Cancer Ther. 2022 Jan;21(1):206-216. doi: 10.1158/1535-7163.MCT-21-0509. Epub 2021 Oct 19. Mol Cancer Ther. 2022. PMID: 34667110 Free PMC article.
Anastrozole, but not exemestane or letrozole, is a ligand for estrogen receptor alpha. The mechanisms of endocrine resistance are heterogenous and with the new mechanism of anastrozole, we have found that treatment of anastrozole maintains fatty acid synthase …
Anastrozole, but not exemestane or letrozole, is a ligand for estrogen receptor alpha. The mechanisms of endocrine resistance are het …
Anastrozole in the management of breast cancer.
Nabholtz JM, Reese D. Nabholtz JM, et al. Expert Opin Pharmacother. 2002 Sep;3(9):1329-39. doi: 10.1517/14656566.3.9.1329. Expert Opin Pharmacother. 2002. PMID: 12186625 Review.
The median duration of survival was 26.7 months for anastrozole versus 22.5 months for megestrol acetate. Anastrozole was as well-tolerated as megestrol acetate, while weight gain was significantly increased in the megestrol acetate group compared with the anastr …
The median duration of survival was 26.7 months for anastrozole versus 22.5 months for megestrol acetate. Anastrozole was as w …
Anastrozole plus fulvestrant vs. anastrozole alone for hormone receptor-positive advanced breast cancer: a meta-analysis of randomized controlled trials.
Li M, Xiong Y, Liao C, He Y, Duan S, Yi F, Wei Y, Zhang W. Li M, et al. Breast Cancer Res Treat. 2020 Apr;180(2):269-278. doi: 10.1007/s10549-020-05551-3. Epub 2020 Feb 1. Breast Cancer Res Treat. 2020. PMID: 32008124 Review.
BACKGROUND: For patients with hormone receptor (HR)-positive advanced breast cancer, whether the combination of anastrozole and fulvestrant is more effective than anastrozole alone is controversial. ...CONCLUSIONS: For HR-positive advanced breast cancer patients, th …
BACKGROUND: For patients with hormone receptor (HR)-positive advanced breast cancer, whether the combination of anastrozole and fulve …
Anastrozole: a selective aromatase inhibitor for the treatment of breast cancer.
Higa GM, alKhouri N. Higa GM, et al. Am J Health Syst Pharm. 1998 Mar 1;55(5):445-52. doi: 10.1093/ajhp/55.5.445. Am J Health Syst Pharm. 1998. PMID: 9522927 Review.
The role of anastrozole, a new selective aromatase inhibitor, in treating hormone-responsive metastatic breast cancer is discussed. ...Anastrozole is cleared principally by the liver. Clinical trials comparing anastrozole with megestrol acetate demonstrated n …
The role of anastrozole, a new selective aromatase inhibitor, in treating hormone-responsive metastatic breast cancer is discussed. . …
2,559 results

Searches related to "anastrozole"